Guided Therapeutics (GTHP) EPS (Diluted) Growth (5y) (2020 - 2025)
Guided Therapeutics (GTHP) EPS (Diluted) Growth (5y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.81 Bn | 175.52 Bn | 6.27 Bn |
| 2 | Stryker | 128.98 Bn | 126.10 Bn | 3.81 Bn |
| 3 | Medtronic | 108.67 Bn | 99.45 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.36 Bn | 66.91 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.70 Bn | 44.03 Bn | 1.29 Bn |
| 6 | Dexcom | 28.67 Bn | 27.55 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.55 Bn | 26.27 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn |
| 10 | Guided Therapeutics | 20.39 Mn | 20.32 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.87% |
| Sep 30, 2025 | -14.87% |
| Jun 30, 2025 | 88.62% |
| Mar 31, 2025 | -14.87% |
| Dec 31, 2024 | -14.87% |
| Sep 30, 2024 | 80.01% |
| Jun 30, 2024 | 88.91% |
| Mar 31, 2024 | 34.91% |
| Dec 31, 2023 | 81.49% |
| Sep 30, 2023 | 30.45% |
| Jun 30, 2023 | -15.10% |
| Mar 31, 2023 | -15.30% |
| Sep 30, 2022 | 84.62% |
| Jun 30, 2022 | 85.48% |
| Mar 31, 2022 | 81.21% |
| Dec 31, 2021 | 66.67% |
| Sep 30, 2021 | 70.57% |
| Jun 30, 2021 | 73.47% |
| Mar 31, 2021 | -69.61% |
| Dec 31, 2020 | 14.87% |